Evergauge and Agilent Technologies Expand Global Marketing Collaboration to Advance CE-MS Solutions for Biopharma and Life Sciences
Recently, CMP Scientific Corp., a subsidiary of Yongdao Zhiyuan Scientific Technology Co., Ltd., signed an agreement with Agilent Technologies to deepen their marketing collaboration. Building on five years of strategic partnership, the two parties will further leverage Yongdao Zhiyuan’s EMASS-II CE-MS coupling technology to provide high-value, comprehensive CE-MS solutions for users worldwide. These solutions will focus on cutting-edge areas in biopharmaceutical and life sciences research, including charge heterogeneity analysis of antibody drugs, identification of impurity peaks in antibody drugs via CE-SDS, proteomics, and metabolomics.
Yongdao Zhiyuan has mastered the core technology of capillary electrophoresis-mass spectrometry (CE-MS) and offers a comprehensive product portfolio encompassing hardware, software, consumables, and reagents. Its products are currently widely applied in biopharmaceuticals, life sciences research, clinical multi-omics studies, and in vitro diagnostics. To date, the company’s innovation centers in New York and Shanghai have provided CE-MS-related products and services to nearly 100 users, including biopharmaceutical companies, academic and research institutions, and healthcare facilities.
The collaboration between the two parties will expand across multiple dimensions, including new customer acquisition, product demonstrations, and post-sales application support. By integrating the ECE-001 Capillary Electrophoresis System and the EMASS-II CE-MS Coupled Ion Source into its solutions, Yongdao Zhiyuan empowers Agilent Technologies’ mass spectrometry users, providing innovative solutions for highly challenging mass spectrometry analyses such as next-generation antibody drug analysis and characterization, ADC drug development, and clinical multi-omics.
Yongdao Zhiyuan’s proprietary EMASS-II CE-MS coupling technology employs a coaxial sheath-flow design driven by an electroosmotic pump, delivering significantly superior detection sensitivity and coupling stability compared to similar products. The excellent performance of the company’s ECE-001 capillary electrophoresis system and the EMASS-II CE-MS ion source has been thoroughly validated by dozens of leading biopharmaceutical companies and medical institutions, with applications spanning cutting-edge fields such as antibody drug analysis and characterization, drug impurity identification, preclinical druggability assessment, proteomics, and metabolomics.
Yongdao Zhiyuan and Agilent Technologies will jointly conduct marketing promotions and user training, while strengthening after-sales technical support in the biopharmaceutical sector. Further deepened collaboration will accelerate the application of the EMASS-II CE-MS coupled technology in cutting-edge mass spectrometry fields, including antibody drug development, proteomics, and metabolomics.
Yongdao Zhiyuan Scientific Technology Co., Ltd. possesses world-leading, globally patented capillary electrophoresis-mass spectrometry (CE-MS) technology and has established hardware R&D and application innovation centers in Silicon Valley, New York, and Shanghai. The company boasts a full-chain R&D team dedicated to the complete system and application development of mass spectrometry instruments. Its core products, including capillary electrophoresis systems, CE-MS ion sources, and integrated CE-MS instruments, have been widely adopted by hundreds of biopharmaceutical companies, life science laboratories, and medical institutions. Since its inception, Yongdao Zhiyuan has secured nearly RMB 100 million in investments from specialized healthcare funds across multiple financing rounds, with a new round of financing currently underway. Company website:www.evergauge.cn。